InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Friday. The brokerage issued a sell rating on the stock.

InspireMD Trading Down 2.0 %

NYSE NSPR opened at $2.39 on Friday. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.85. The stock has a 50-day moving average of $2.43 and a 200-day moving average of $2.51. The firm has a market cap of $59.58 million, a PE ratio of -3.14 and a beta of 0.96.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). InspireMD had a negative net margin of 350.35% and a negative return on equity of 55.12%. The company had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.38 million. During the same period last year, the firm posted ($0.53) EPS. As a group, equities research analysts forecast that InspireMD will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in InspireMD stock. McKinley Carter Wealth Services Inc. purchased a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $28,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.